Poster details data from aTyr’s pre-clinical, domain specific Neuropilin-2 (NRP2) antibody program highlighting therapeutic potential in triple-negative breast cancer SAN DIEGO , May 20, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery

Company to host conference call and webcast today, May 12, at 5:00 p.m. EDT / 2:00 p.m. PDT SAN DIEGO , May 12, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological

Management to host conference call and webcast on May 12th at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , May 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways,

Abstracts originally accepted for presentation at the 2020 American Thoracic Society (ATS) International Conference Findings confirm that aTyr’s lead clinical candidate, ATYR1923, selectively binds to Neuropilin-2 (NRP2), a unique target expressed on key immune cells in inflammatory conditions SAN

SAN DIEGO , April 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the U.S. Food and Drug Administration (FDA) has accepted its

Company to host conference call and webcast today at 5:00 p.m. EDT / 2:00 p.m. PDT SAN DIEGO , March 26, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

Grant awarded by the Hong Kong Government's Innovation and Technology Commission under the Partnership Research Program Two-year project will initially focus on development of new bi-specific antibodies targeting NRP2 SAN DIEGO , March 24, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

Management to host conference call and webcast at 5:00 pm EST / 2:00 pm PST SAN DIEGO , March 19, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

Dr. Mercurio to advise company on the development of novel antibody therapeutics targeting neuropilin-2 (NRP2) for cancer SAN DIEGO , March 17, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based

SAN DIEGO , March 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the underwriters of its previously announced public offering of common